Penn Medicine Awarded $6 Million to Advance Understanding of Human Genome Function in Health and Disease

Penn Medicine is one of 30 sites chosen by the National Institute of Health to serve as an Impact of Genomic Variation on Function investigator.

Article from Penn Medicine

FDA clears first-of-its-kind tri­al to see if CRISPR gene edit­ing can cure HIV

The FDA has cleared a company attempting to use CRISPR gene-editing to cure HIV to begin clinical trials.

Article from Endpoints News

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease

A biotechnology company has announced the start of Phase 2 trial in the development of the first vaccine against MERS.

Article from PR Newswire

Aro Biotherapeutics Expands Leadership Team and Plans Move to New Philadelphia Headquarters to Drive Next Phase of Growth

A biotechnology company pioneering the development of tissue-targeted genetic medicines has announced their three new executive leaders and headquarter relocation to Philadelphia.

Article from Aro Biotherapuetics

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

A clinical-stage biopharmaceutical company has announced the completion of a new development.

Article from Business Wire

Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease Patients

A biopharmaceutical company announced the results of a Phase 1b of CERC-002.

Article from GlobeNewswire

Penn Medicine Discovery Clarifies the Problem of T-Cell “Exhaustion”

Researchers in the Perelman School of Medicine have made new findings in immune-based therapy research.

Article from Penn Medicine News

Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date

Member of the Roche Groupe, Spark Therapeutics, announced their updated data to challenge the inevitability of genetic disease.

Article from Spark Therapeutics

NextUp: Biopharma Company Engineering T-Cell Receptors to Destroy Cancerous Solid Tumors

The Navy Yard-Based Biopharma Company is on track to file for their drug candidate, afami-cel, for FDA approval next year.

Article from Philly Mag

Life sciences companies sign HQ leases in Chester County as deals begin to pick up

Three life sciences companies have leased space for their headquarters, making long-term commitments to the Philadelphia region.

Article from Philadelphia Business Journal